Form 4: Labcorp CEO Adam Schechter Reports Stock Transactions

Labcorp CEO Adam Schechter reports the acquisition and disposal of company stock and derivative securities.

Summary

• On February 11, 2025, Adam Schechter, the President & CEO of Labcorp Holdings Inc., reported several transactions involving the company's stock.
• These transactions included the sale of 6,121 shares of common stock at $244.62 per share, the acquisition of 2,963 shares through the vesting of restricted stock units, and a stock withholding of 1,226 shares at $245.14 to cover tax obligations.
• Schechter also acquired 33,100 non-qualified stock options and 10,970 restricted stock units.
• Following these transactions, Schechter beneficially owns 88,182 shares of common stock, 33,100 non-qualified stock options, and 23,139 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions. The sale of shares is balanced by the acquisition of options and RSUs.

Positives

• The acquisition of 33,100 non-qualified stock options indicates a long-term commitment to the company's success.
• The acquisition of 10,970 Restricted Stock Units (RSUs) that will vest in three equal annual installments beginning February 11, 2026, aligns Schechter's interests with shareholders.

Negatives

• The sale of 6,121 shares, while potentially part of a pre-arranged plan, could be interpreted negatively by some investors.

Risks

• There are no specific risks mentioned in this document, but insider trading activity is always subject to scrutiny and potential legal challenges if not properly executed under Rule 10b5-1.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the restricted stock units and the expiration date of the stock options suggest a multi-year commitment from the CEO.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for executives to have stock options and RSUs as part of their compensation packages, and their transactions are closely monitored by regulators and investors.

Comparison to Industry Standards

• Executive compensation packages in the healthcare industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedules and exercise prices of these instruments are generally comparable to those offered by peer companies such as Quest Diagnostics (DGX) and UnitedHealth Group (UNH).
• The use of Rule 10b5-1 plans is a common practice among corporate executives to avoid accusations of insider trading.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are interpreted.
• Employees may view the CEO's stock ownership and options as a sign of confidence in the company's future.

Key Dates

Keywords

Labcorp, Adam Schechter, Stock Options, Restricted Stock Units, Insider Trading, Form 4, Securities Exchange Act, Beneficial Ownership